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effectiveness ratio (ICER) of $84,000 per quality-adjusted
life year (QALY) gained. When considering the beneﬁts
of DES, incremental costs increased to $3300 and beneﬁt
of UNIV increased to 18 QALDs, with an ICER of
$69,000/QALY. Results were similar for women and over
a broad age range (55–75 years). If we assumed that PCI
in functionally insigniﬁcant stenoses did not reduce long-
term mortality, the ICER for UNIV vs. TEST was >$1
million/QALY. CONCLUSIONS: Regardless of stent type
(BMS or DES), measuring FFR to guide the decision to
perform PCI leads to signiﬁcant cost savings. Even under
very optimistic assumptions regarding mortality beneﬁts
and restenosis rates for DES, universal stenting does not
appear to be cost-effective when compared to other well-
accepted interventions in health care.
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OBJECTIVE: The objective of this analysis is to assess
the cost and quality of life of patients treated for hyper-
cholesterolemia in Germany. METHODS: The following
analysis uses the baseline data assessed at the begin-
ning of the randomised controlled German ORBITAL
study, designed to determine the impact of a compliance-
enhancing program on long-term disease-related out-
comes and costs. More than 8000 patients with
hypercholesterolemia (HC) eligible for statin therapy
have been enrolled. At baseline patients completed a
detailed questionnaire. Health care resource use over 
the past 6 months, preceding enrolment, as well as quality
of life (SF-12, EQ-5D and EQ-VAS) was assessed.
RESULTS: A total of 2500 patients (mean age 61 ± 11
years, 44% female) were included in this analysis, 32%
were employed at the time of inclusion, 19% had a
history of myocardial infarction, 8% a history of stroke,
61% had hypertension and 28% diabetes. Disease-related
direct costs amounted to a mean of €655 per patient in
the six months period, indirect costs to €1495 per patient.
Direct costs included mainly costs for hospital stays
(€433), primary care consultations (€111), outpatient
therapeutic measures (€54), and rehabilitation (€43).
Indirect costs due to days off work amounted to €303,
due to early retirement to €1191. Mean quality of life
according to the EQ-5D was 0.81 (EQ-VAS 0.69). The
mean scores of the SF-12 were 47.60 (PCS) and 43.24
(MCS). CONCLUSIONS: Indirect costs due to a loss of
productivity contributed markedly to the disease-related
costs in patients with HC. The considerable economic
burden of HC indicates the need to assess long-term effec-
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OBJECTIVES: To carry out a systematic review of the lit-
erature comparing the cost-effectiveness of thrombolytic
agents currently available in the UK for treatment of AMI
in either a hospital or pre-hospital setting. The aim of 
this review was to identify economic evaluations that 
had been undertaken in the context of high quality ran-
domised controlled trials in order to inform UK NHS
decision-making. METHODS: The search included a
number of strategies. Search terms for electronic data-
bases (MEDLINE, EMBASE, HTA, DARE, NHS-EED,
Cochrane Trials Register) included a combination of
index terms and free word text. Using explicit, predeter-
mined criteria, two reviewers independently identiﬁed
studies for inclusion in the cost-effectiveness review
process. Quality assessment using the Drummond 10-
point checklist was also performed. RESULTS: No
studies in the pre-hospital setting met the inclusion crite-
ria. In the hospital setting, 107 papers were considered
for inclusion in the review and 8 met the inclusion crite-
ria. All of the studies justiﬁed their choice of comparator,
performed incremental cost-effectiveness analysis and
included relevant comparators. Authors in Europe
applied the results of the GUSTO I study to their own 
settings in an attempt to compare the cost-effectiveness
of alteplase versus streptokinase. Consequently, cost-
effectiveness ratios were expressed in several currencies,
a reﬂection of the international interest in the choice
between alteplase and streptokinase. Some studies did not
sufﬁciently explore the true cost of complications over the
patient’s lifetime, nor was this addressed fully by sensi-
tivity analysis. Only three studies considered issues that
can be addressed by cost-utility analyses. Overall the
studies were of good quality. CONCLUSIONS: Existing
economic evaluations are of limited value in determining
the relative cost-effectiveness of thrombolytic drugs in the
NHS. Published studies are almost all industry funded
and interpretation of results depends on whether one
accepts or rejects the assumption of superiority of
alteplase over streptokinase.
